Skip to content
DataLookout
Menu

PIILLNCT04073797

PET Imaging of Inflammation and Lipid Lowering Study

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Oct 1, 2025 to May 30, 2026 Show 6 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Trial status changed: Unknown → Completed
    • Enrollment target: estimated 63 to confirmed 60
    • Site details revised
    • Collaborators: 4 to 5
    • Publications: details revised at 2 of 2 entries
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary completion date: Mar 1, 2025 to Oct 1, 2025
    • Trial status: Recruiting to Unknown
    • Study completion date: Mar 1, 2025 to Mar 1, 2026
    v7
  4. Notable Trial status: Not Yet Recruiting to Recruitingv6 Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Start date changed from estimate of Mar 1, 2023 to Mar 20, 2023
    • Study description expanded, about 64 words
    • Site details revised
    • Collaborators: 2 to 4
  5. Notable Primary and study completion dates pushed to Mar 1, 2025v5 Show 9 more changesShow less
    • Start date: Aug 20, 2021 to Mar 1, 2023
    • Eligibility criteria expanded, about 63 words
    • Trial status: Recruiting to Not Yet Recruiting
    • Enrollment target: 56 to 63
    • Interventions: 68Ga-DOTATATE PET-MRI (Diagnostic Test), PCSK9 inhibitor (Drug) to 68Ga-DOTATATE PET-MRI (Diagnostic Test), Colchicine (Drug), Inclisiran (Drug)
    • Secondary endpoints revised (3)
    • Study description expanded, about 13 words
    • Site details revised
    • Study arms: 4 to 3
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2023 to Mar 1, 2023
    • Study completion date: Oct 1, 2023 to Mar 1, 2024
    • Start date changed from estimate of Jul 1, 2021 to Aug 20, 2021
    • Site details revised
  2. Notable Start date: Oct 1, 2019 to Jul 1, 2021v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Carotid 68Ga-DOTATATE PET
Timeframe: 12 weeks
Carotid UPSA imaging
Timeframe: 12 weeks

Secondary (3)

MRI plaque burden
Carotid 68Ga-DOTATATE vs. serum lipids
Carotid 68Ga-DOTATATE vs. hsCRP

Arms and interventions

Stable CVD - treatmentExperimental

Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to add on therapy with inclisiran + placebo tablet

Stable CVD - placebo controlActive comparator

Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + colchicine tablet

HeFH - treatmentPlacebo comparator

Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + placebo tablet

Drugs: Inclisiran, Colchicine

Diagnostic tests: 68Ga-DOTATATE PET-MRI

Sites

1 site in 1 country

  • University of CambridgeCambridge, United Kingdom